Abstract
Protein tyrosine phosphatase (PTP) catalytic domains undergo a series of conformational changes in order to mediate dephosphorylation of their tyrosine phosphorylated substrates. An important conformational change occurs in the Tryptophan-Proline-Aspartic acid (WPD) loop, which contains the conserved catalytic aspartate. Upon substrate binding, the WPD loop transitions from the ‘open’ to the ‘closed’ state, thus allowing optimal positioning of the catalytic aspartate for substrate dephosphorylation. The dynamics of WPD loop conformational changes have previously been studied for PTP1B, HePTP, and the bacterial phosphatase YopH, but have not yet been comprehensively studied for the nonreceptor tyrosine phosphatase SHP-1 (PTPN6). To structurally describe the changes in WPD loop conformation in SHP-1, we have determined the 1.4 Å crystal structure of the catalytic domain of SHP-1 in the Apo state and the 1.8 Å crystal structure of the SHP-1 catalytic domain in complex with a phosphate ion. We provide structural analysis for the WPD loop closed state of SHP phosphatases and the conformational changes that occur upon WPD loop closure.
Keywords: Protein tyrosine phosphatase, WPD loop, conformational changes, cytokine signaling.
Protein & Peptide Letters
Title:SHP Family Protein Tyrosine Phosphatases Adopt Canonical Active-Site Conformations in the Apo and Phosphate-Bound States
Volume: 20 Issue: 9
Author(s): Nilda L. Alicea-Velazquez and Titus J. Boggon
Affiliation:
Keywords: Protein tyrosine phosphatase, WPD loop, conformational changes, cytokine signaling.
Abstract: Protein tyrosine phosphatase (PTP) catalytic domains undergo a series of conformational changes in order to mediate dephosphorylation of their tyrosine phosphorylated substrates. An important conformational change occurs in the Tryptophan-Proline-Aspartic acid (WPD) loop, which contains the conserved catalytic aspartate. Upon substrate binding, the WPD loop transitions from the ‘open’ to the ‘closed’ state, thus allowing optimal positioning of the catalytic aspartate for substrate dephosphorylation. The dynamics of WPD loop conformational changes have previously been studied for PTP1B, HePTP, and the bacterial phosphatase YopH, but have not yet been comprehensively studied for the nonreceptor tyrosine phosphatase SHP-1 (PTPN6). To structurally describe the changes in WPD loop conformation in SHP-1, we have determined the 1.4 Å crystal structure of the catalytic domain of SHP-1 in the Apo state and the 1.8 Å crystal structure of the SHP-1 catalytic domain in complex with a phosphate ion. We provide structural analysis for the WPD loop closed state of SHP phosphatases and the conformational changes that occur upon WPD loop closure.
Export Options
About this article
Cite this article as:
Alicea-Velazquez L. Nilda and Boggon J. Titus, SHP Family Protein Tyrosine Phosphatases Adopt Canonical Active-Site Conformations in the Apo and Phosphate-Bound States, Protein & Peptide Letters 2013; 20 (9) . https://dx.doi.org/10.2174/09298665113209990041
DOI https://dx.doi.org/10.2174/09298665113209990041 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological and Pharmacological Activities of Carvacrol and Carvacrol Bearing Essential Oils
Current Pharmaceutical Design Anticancer Activity of New Haloalkyl Camptothecin Esters against Human Cancer Cell Lines and Human Tumor Xenografts Grown in Nude Mice
Anti-Cancer Agents in Medicinal Chemistry From Ocean to Bedside: the Therapeutic Potential of Molluscan Hemocyanins
Current Medicinal Chemistry Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Bone Changes in Patients with Inflammatory Arthritis Treated with Biological Therapies: A Clinical Perspective
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection <i>via</i> Microarray Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Heparan Sulphate as a Regulator of Leukocyte Recruitment in Inflammation
Current Protein & Peptide Science Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS)
Recent Patents on Anti-Cancer Drug Discovery Phytochemical Characterization of Prickly Pear (Opuntia spp.) and of its Nutritional and Functional Properties: A Review
Current Nutrition & Food Science Chemically Synthesized Matrix Metalloproteinase and Angiogenesis-inhibiting Peptides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry The Potential Role of Radiation Therapy in Bowens Disease: A Review of the Current Literature
Reviews on Recent Clinical Trials Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Structural Analysis for Colchicine Binding Site-Targeted ATCAA Derivatives as Melanoma Antagonists
Medicinal Chemistry Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines
Current Pharmaceutical Design Vitamins and Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Secreted Heat Shock Protein-90α: A More Effective and Safer Target for Anti-Cancer Drugs?
Current Signal Transduction Therapy